Galectin Therapeutics CMO Sells Shares as Institutional Investors Adjust Positions
Khurram Jamil, Galectin's Chief Medical Officer, sold 2,533 shares, while major funds adjusted their holdings.
Key Points
- Chief Medical Officer Khurram Jamil sold 2,533 shares of Galectin Therapeutics on June 26, 2026.
- Galectin Therapeutics, trading at $4.64, has a market cap of $328.6 million and a 52-week range of $2.03 to $7.13.
- Vanguard Capital Management opened a new position in Galectin, while other funds like Marshall Wace increased their stakes.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Khurram Jamil, the Chief Medical Officer of Galectin Therapeutics Inc. (NasdaqCM: GALT), sold 2,533 shares of the company on June 26, 2026. This transaction was not part of a pre-planned trading program.
Insider Buying and Selling at Galectin Therapeutics Inc.
On June 26, 2026, Khurram Jamil, the Chief Medical Officer of Galectin Therapeutics, sold 2,533 shares. This sale was not conducted under a Rule 10b5-1 trading plan. Additionally, on June 29, 2026, Jamil bought 47,467 shares at $2.50 per share and sold the same number at $5.04 under a planned transaction. Harold Shlevin, another insider, also made transactions on June 29, buying 22,268 shares at $1.23 and selling the same amount at $5.04 under a planned sale.
Other Institutional Activity in Galectin Therapeutics
Vanguard Capital Management LLC opened a new position in Galectin Therapeutics, acquiring 1,966,542 shares valued at approximately $5.49 million. Marshall Wace, LLP increased its holdings by 617,778 shares, bringing its total to 1,219,912 shares worth about $3.40 million, marking a 102.6% increase. Osaic Holdings, Inc. added 32,080 shares, ending with 1,122,670 shares valued at $3.13 million, a 2.9% increase. BlackRock, Inc. slightly boosted its stake by 2,679 shares to hold 799,237 shares valued at $2.23 million. Meanwhile, Millennium Management LLC significantly increased its holdings by 562,926 shares, reaching a total of 798,434 shares worth $2.23 million, reflecting a 239% increase.
Galectin Therapeutics Inc. Stock Up 17.5%
Shares of Galectin Therapeutics Inc. traded near $4.64 on Wednesday. The company, with a market capitalization of $328.6 million, operates in the biotechnology sector. It has a 52-week low of $2.03 and a high of $7.13. The stock's 50-day moving average is $2.53, while its 200-day moving average is $3.72. Galectin's beta is 0.494, indicating lower volatility compared to the market. The company has a current ratio of 2.147 and a quick ratio of 1.931.
$GALT stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 23, 2026, HC Wainwright & Co. reiterated its buy rating on Galectin Therapeutics with a price target of $11. The firm has consistently maintained a buy rating with the same target in previous updates. Currently, one analyst covers the stock with a mean price target of $11.00.
About Galectin Therapeutics
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Norcross, Georgia. It focuses on developing therapies for fibrotic diseases and cancer. The company's main product candidate, belapectin, is a galectin-3 inhibitor being tested in Phase 2 clinical trials for patients with advanced fibrosis and compensated cirrhosis. Galectin collaborates with SBH Sciences to explore galectin-3 inhibitors for oral use.
Bottom Line
Insider activity at Galectin Therapeutics, including recent sales by its Chief Medical Officer, has drawn attention. At the same time, institutional investors are adjusting their holdings, with some funds initiating new positions. It is important to remember that 13F filings and insider transactions reflect past actions and may not indicate current positions or future intentions.
Get Galectin Therapeutics Inc. alerts
New 13F filings, insider trades, and analyst moves on $GALT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.